Masato Yoshizawa to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Masato Yoshizawa has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
1.051
-
Yoshizawa M, Miyawaki Y, Sato H, Kawasaki T, Furube T, Matsui K, Suzuki Y, Toriumi T, Kishimoto Y, Ebara G, Hirano Y, Okamoto K, Sakuramoto S. Esophageal Lymphoepithelioma-like Carcinoma With a Remarkable Response to DCF Chemotherapy: A Case Report. Anticancer Res. 2025 Oct; 45(10):4643-4652.
Score: 0.802
-
Matsui K, Miyawaki Y, Kobayashi R, Yoshizawa M, Toriumi T, Ebara G, Sato H, Sakuramoto S. Clinical advantages of two vs. three courses of neoadjuvant chemotherapy using docetaxel?+?cisplatin?+?5-fluorouracil to improve preoperative nutritional status and mitigate decreasing skeletal muscle in resectable esophageal cancer. Int J Clin Oncol. 2025 Oct; 30(10):1992-2002.
Score: 0.198
-
Matsui K, Miyawaki Y, Suzuki Y, Furube T, Yoshizawa M, Toriumi T, Ebara G, Sato H, Sakuramoto S. Relationship between immune-related adverse events and long-term survival in patients treated with immune checkpoint inhibitors for unresectable advanced or recurrent esophageal cancer. Dis Esophagus. 2026 Mar 02; 39(2).
Score: 0.052